German Atherosclerosis Society

3rd Thrombosis Meeting Freiburg

Antithrombotic therapy is one of the cornerstones of cardiovascular medicine. Much has changed within recent years and direct-acting oral anticoagulants are now the first choice for many patients requiring antithrombotic therapy.

With the 3rd Thrombosis Meeting Freiburg, we will take a close look at state-of-the-art inhibition of platelets and coagulation factors.

Going beyond current concepts, we also want to discuss the most recent discoveries in thrombus biology, like the interplay between known clot components and the complement system – and, of course, NETs.

We will also talk about external influences that can change hemostasis dramatically, like the acquired von Willebrand syndrome in critically ill patients under ECMO support. Finally, illustrating novel antithrombotic targets may motivate us to further improve patient care.


Best regards,

Prof. Dr. Dr. h.c. Christoph Bode

Prof. Dr. Daniel Dürschmied


to register online, please go to:


Dieser Artikel wurde am 06.02.2018 in der Kategorie News veröffentlicht.